{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:20:54Z","timestamp":1770506454599,"version":"3.49.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2009,7,1]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>  The 17\u03b2-hydroxysteroid dehydrogenases (17\u03b2-HSDs) are involved in the regulation of estrogens and androgens by catalyzing the reduction of 17-ketosteroids or the oxidation of 17\u03b2-hydroxysteroids. The enzyme activities associated with the different 17\u03b2-HSD isoforms are widespread in human tissues, not only in classic steroidogenic tissues but also in a large series of peripheral intracrine tissues. Being involved at the end of steroidogenesis, the numerous members of 17\u03b2-HSD family constitute interesting therapeutic targets for controlling the concentration of estrogens and androgens. Thus, inhibitors of reductive 17\u03b2-HSD isoforms are attractive to block the formation of hydroxysteroids that stimulate estrogeno-sensitive pathologies (breast, ovarian, and endometrium cancers) and androgenosensitive pathologies (prostate cancer, benign prostatic hyperplasia, acne, and hirsutism). The inhibitors could be used to block the degradation of estradiol, an attractive strategy for treating osteoporosis and Alzheimers disease. In addition to their classical use as anti-cancer agents and therapeutic agents, inhibitors of 17\u03b2-HSDs are also useful tools to elucidate the role of these enzymes in particular biological systems. The present review article gives a description of novel inhibitors of 17\u03b2-HSDs that were published in 2003-2006.          <\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/187152009788680000","type":"journal-article","created":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T13:07:30Z","timestamp":1345036050000},"page":"642-660","source":"Crossref","is-referenced-by-count":52,"title":["Advances in Development of Inhibitors of 17\u03b2-Hydroxysteroid Dehydrogenases"],"prefix":"10.2174","volume":"9","author":[{"given":"Donald","family":"Poirier","sequence":"first","affiliation":[{"name":"Laboratory of Medicinal Chemistry, Oncology and Molecular Endocrinology, CHUQ (CHUL) Research Center, 2705 Laurier Boulevard, Quebec (Quebec), G1V 4G2, Canada., Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/69558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/69558\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/69558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T05:26:25Z","timestamp":1618550785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/69558\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,1]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,7,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/187152009788680000","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7,1]]}}}